Splash Beverage Group Acquires Global Rights to CannEpil Therapeutic
Splash Beverage Group (SBEV) has acquired global rights to CannEpil, a patented cannabinoid-based treatment for drug-resistant epilepsy approved in several European countries. The company also secured financing and obtained a 20-year license from Argent BioPharma Limited.
Tickers: $RGT
Topics: cannabinoids epilepsy treatment licensing